BTLA Antikörper (Alexa Fluor 647)

Produktnummer ABIN2657718

Produktdetails anti-BTLA Antikörper (Alexa Fluor 647)

Target: BTLA (B and T Lymphocyte Associated (BTLA))

Reaktivität: Maus

Wirt: Armenischer Hamster

Klonalität: Monoklonal

Konjugat: Dieser BTLA Antikörper ist konjugiert mit Alexa Fluor 647

Applikation: Flow Cytometry (FACS)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.

Klon: 6A6

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C

Details zu BTLA

Target: BTLA (B and T Lymphocyte Associated (BTLA))

Andere Bezeichnung: CD272 (BTLA Produkte)

Synonyme: BTLA antikoerper, BTLA1 antikoerper, CD272 antikoerper, A630002H24 antikoerper, B and T lymphocyte associated antikoerper, BTLA antikoerper, Btla antikoerper

Hintergrund: CD272, also known as B and T lymphocyte attenuator (BTLA), is an Ig superfamily co-inhitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand herpes virus entry mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significantly higher expression of BTLA compared with effectors and naive T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It was reported that BTLA may regulate T cell function by binding to B7-H4, but further studies are needed to confirm. The existence of three distinct BTLA alleles has been reported.

Pathways: Cancer Immune Checkpoints